Statistics from Altmetric.com
Onakpoya IJ, Spencer EA, Thompson MJ, et al. Effectiveness, safety and costs of orphan drugs: an evidence-based review. BMJ Open 2015;24;5:e007199. There have been corrections to the online supplement as follows:
In Appendix 1, Orphacol has been added to the list, and the appropriate references used in the quality and level of the evidence for Orphacol and Cholic Acid FGK are:
Cholic Acid FGK: European Medicines Agency. Assessment report. Cholic acid FGK. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002081/WC500165386.pdf
Orphacol: European Medicines Agency. Orphacol, INN-cholic acid - Annex 1. Summary of product characteristics http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/001250/WC500150993.pdf
In Appendix 2, table 2, the authors have revised the indications for Orphacol, and added ‘deficiency’ to the indication for Cholic Acid FGK:
Cholic Acid FGK: IEM in primary bile acid synthesis due to Sterol 27-hydroxylase deficiency.
Orphacol: IEM in primary bile acid synthesis due to 3beta-Hydroxy-delta5-C27-steroid oxidoreductase deficiency or delta4-3-Oxosteroid-5beta-reductase.
In Appendix 2, table 2, and in Appendix 3, the authors have revised the annual cost of Litak to £835 (1 cycle) based on correspondence with the manufacturers.
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.